kwic
important
important
right
off
ON
298
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for important out of >500 occurrences
448856 occurrences (No.37 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to important]
448856 occurrences (No.37 in the rank) during 5 years in the PubMed. [cache]
| 298) Calcitonin gene-related peptide receptor antagonists represent a potentially important alternative means of treating acute migraine. |
| PMID:24382126 DOI:10.1111/papr.12158 |
| 2015 Pain practice : the official journal of World Institute of Pain |
| * Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. |
| - Although triptans are widely used for treating acute migraine, they are contraindicated or not effective in a large proportion of patients. Hence, alternative treatments are needed. Calcitonin gene-related peptide receptor antagonists, such as telcagepant, have been under investigation as a treatment for acute migraine. A meta-analysis of the efficacy of telcagepant vs. placebo and triptans (zolmitriptan or rizatriptan) was performed. Randomized controlled trials were indentified from databases using the following search terms: migraine; calcitonin gene-related peptide; calcitonin gene-related peptide receptor antagonists; efficacy; safety, and telcagepant. The primary outcome measure was pain freedom 2 hours after first treatment. The secondary outcome measure was pain relief 2 hours after first treatment. Eight trials were included in the meta-analysis (telcagepant = 4011 participants). The difference in pain freedom at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.70, 95% confidence interval = 2.27-3.21, P < 0.001) and triptans over telcagepant (odds ratio = 0.68, 95% confidence interval = 0.56-0.83, P < 0.001). The difference in pain relief at 2 hours significantly favored telcagepant over placebo (odds ratio = 2.48, 95% confidence interval = 2.18-2.81, P < 0.001). The difference in pain relief at 2 hours did not significantly favor telcagepant over triptans or vice versa (odds ratio = 0.76, 95% confidence interval = 0.57-1.01, P = 0.061). These findings indicate that telcagepant can be effective for treating acute migraine. Calcitonin gene-related peptide receptor antagonists represent a potentially important alternative means of treating acute migraine. |
[
right
kwic]
(1)65  role |
(16)4 data |
(31)2 alternative |
(46)2 indicator |
| (2)37 for |
(17)4 differences |
(32)2 aspect |
(47)2 mechanism |
| (3)34 to |
(18)3 approach |
(33)2 baseline |
(48)2 model |
| (4)28 in |
(19)3 causes |
(34)2 because |
(49)2 molecular |
| (5)15 implications |
(20)3 clinical |
(35)2 bivalve, |
(50)2 not |
| (6)11 factor |
(21)3 findings |
(36)2 complication |
(51)2 pathogen |
| (7)9 *null* | (22)3 genes |
(37)2 components |
(52)2 phenomenon |
| (8)9 and |
(23)3 health |
(38)2 consequences |
(53)2 physiological |
| (9)8 determinants |
(24)3 human |
(39)2 contributor |
(54)2 protective |
| (10)8 roles |
(25)3 insights |
(40)2 coping |
(55)2 route |
| (11)7 factors |
(26)3 policy |
(41)2 determinant |
(56)2 standard |
| (12)6 cause |
(27)3 predictors |
(42)2 economic |
(57)2 step |
| (13)5 component |
(28)3 public |
(43)2 element |
(58)2 strategic |
| (14)5 risk |
(29)3 when |
(44)2 fish |
(59)2 subset |
| (15)4 as |
(30)2 DNA |
(45)2 function |
(60)2 target |
add keyword
--- WordNet output for important ---